Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
NCT06206278 · LianBio LLC · PHASE2 · terminated · last registry update 2024-08-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business Reason” | – | Registry record, LianBio LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-01Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib + Investigator Choice (Gemcitabine) (NCT04172675)
- 2025-06-10Results posted on the registry: Sameek Roychowdhury, Infigratinib (NCT04233567)
- 2025-05-20Results posted on the registry: Boehringer Ingelheim, Nintedanib + Placebo (NCT05065190)
- 2025-05-14Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib + Vinflunine (NCT03390504)
- 2025-05-02Results posted on the registry: M.D. Anderson Cancer Center, Pazopanib Hydrochloride (NCT01436227)
- 2025-04-30Also stopped (terminated): University of Washington, Sirolimus Albumin-bound Nanoparticles + Pazopanib hydrochloride (NCT03660930)
- 2025-04-18Results posted on the registry: European Association of Urology Research Foundation, Pemigatinib (NCT04294277)
- 2025-04-18Also stopped (terminated): European Association of Urology Research Foundation, Pemigatinib (NCT04294277)
- 2025-04-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, Nintedanib + Prednisone (NCT02496585)
- 2025-04-13Phase 3 first posted: Kyowa Kirin Co., Ltd., KK8398 (NCT06926491)
- 2025-04-13Also stopped (terminated): Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Pemigatinib (NCT05565794)
- 2025-04-09Phase 3 first posted: Janssen Research & Development, LLC, TAR-210 + Mitomycin C (NCT06919965)
- 2025-03-25Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Nivolumab + Ipilimumab (NCT03377023)
- 2025-03-12Phase 3 first posted: QED Therapeutics, a BridgeBio company, infigratinib 0.128 mg/kg/day + infigratinib 0.25 mg/kg/day (NCT06873035)
- 2025-03-06Also stopped (terminated): Boehringer Ingelheim, BIBF 1120 M + Pemetrexed + BIBF 1120 H + Pemetrexed (NCT00979576)
- 2025-02-24Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib (NCT04083976)
- 2025-02-24Also stopped (withdrawn): West Virginia University, Nintedanib + Placebo (NCT05067517)
- 2025-02-13Also stopped (terminated): Boehringer Ingelheim, docetaxel + docetaxel (NCT02231164)
- 2025-02-07Results posted on the registry: Taiho Oncology, Inc., Futibatinib + Cisplatin (NCT04093362)
- 2025-02-07Also stopped (terminated): Taiho Oncology, Inc., Futibatinib + Cisplatin (NCT04093362)
- 2025-02-03Also stopped (terminated): Boehringer Ingelheim, Nintedanib + Capecitabine (NCT02780700)
- 2025-02-03Also stopped (terminated): Janssen Research & Development, LLC, Erdafitinib (NCT03587363)
- 2025-01-03Results posted on the registry: Vicore Pharma AB, Drug Drug Interaction (NCT05830799)
- 2025-01-01Results posted on the registry: M.D. Anderson Cancer Center, Infigratinib (NCT04228042)
- 2025-01-01Also stopped (terminated): M.D. Anderson Cancer Center, Infigratinib (NCT04228042)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision